GC
VIRX

Guggenheim Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Guggenheim Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-637
Closed -$97K – 2992
2016
Q3 		$97K Buy
637
+518
+435% +$73.1K ﹤0.01% 2732
2016
Q2 		$14K Hold
119
– – ﹤0.01% 2830
2016
Q1 		$14K Buy
119
+65
+120% +$9.85K ﹤0.01% 2850
2015
Q4 		$10K Hold
54
– – ﹤0.01% 2944
2015
Q3 		$9K Buy
+54
New +$19.5K ﹤0.01% 2931
2015
Q2 		– Sell
-80
Closed -$41K – 3103
2015
Q1 		$41K Buy
80
+3
+4% +$1.51K ﹤0.01% 2947
2014
Q4 		$41K Buy
+77
New +$34.7K ﹤0.01% 2935
2014
Q3 		– Sell
-101
Closed -$139K – 3140
2014
Q2 		$139K Sell
101
-10
-9% -$11.6K ﹤0.01% 2959
2014
Q1 		$155K Buy
111
+27
+32% +$31.4K ﹤0.01% 2947
2013
Q4 		$84K Buy
84
+11
+15% +$11.4K ﹤0.01% 3003
2013
Q3 		$76K Sell
73
-1
-1% -$1.07K ﹤0.01% 2893
2013
Q2 		$81K Buy
+74
New +$82.5K ﹤0.01% 2849

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Guggenheim Capital's VIRX Position: Q4 2016 in Review

Guggenheim Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2016, closing a stake of 637 shares — an estimated $97K sold.

Guggenheim Capital first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $155K in Q1 2014. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

  • Guggenheim Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 637 Viracta Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $97K.
  • Guggenheim Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
  • Guggenheim Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $155K in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.